Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues

Greet Van Den Berghe, Francis De Zegher, Robert C. Baxter, Johannes D Veldhuis, Pieter Wouters, Miet Schetz, Charles Verwaest, Erik Van Der Vorst, Peter Lauwers, Roger Bouillon, Cyril Y. Bowers

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

The catabolic state of prolonged critical illness is associated with a low activity of the thyrotropic and the somatotropic axes. The neuroendocrine component in the pathogenesis of these low activity states was assessed by investigating the effects of continuous intravenous infusions of TRH, GH- releasing peptide-2 (GHRP-2), and GHRH. Twenty adult patients, critically ill for several weeks, were studied during two consecutive nights. They had been randomly allocated to one of three combinations of peptide infusions, each administered in random order: TRH (one night) and placebo (other night), TRH + GHRP-2 (one night) and GHRP-2 (other night), or TRH + GHRH + GHRP-2 (one night) and GHRH + GHRP-2 (other night). The peptide infusions were started after a 1-μg/kg bolus and infused (1 μg/kg per h) until 0600 h. Blood sampling was performed every 20 min, and pituitary hormone secretion was quantified by deconvolution analysis. Reduced pulsatile fraction of TSH, GH, and PRL secretion and low serum concentrations of T4, T3, insulin growth factor-I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were documented in the untreated state. Infusion of TRH alone or in combination with GH secretagogues augmented nonpulsatile TSH release 2- to 5-fold; only TRH + GHRP-2 increased pulsatile TSH secretion (4-fold). Average rises in T4 (40-54%) and in T3 (52-116%) were obtained with all three combinations, whereas reverse T3 levels did not increase, except when TRH was infused alone. Pulsatile GH secretion was amplified >6- and > 10- fold, respectively, by GHRP-2 and GHRH + GHRP-2 infusions, generating mean increases of serum IGF-I (66% and 106%), IGFBP-3 (50% and 56%), and ALS (65% and 97%) within 45 h. The addition of TRH did not alter the GH secretory patterns. TRH infusion increased PRL release only when combined with GH secretagogues. No effects on serum cortisol were detected. In conclusion, the pathogenesis of the low activity state of the thyrotropic and somatotropic axes in prolonged critical illness appears to have a neuroendocrine component, because these axes are both readily activated by coinfusion of TRH and GH secretagogues.

Original languageEnglish (US)
Pages (from-to)309-319
Number of pages11
JournalJournal of Clinical Endocrinology and Metabolism
Volume83
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Neuroendocrinology
Thyrotropin-Releasing Hormone
Critical Illness
Growth Hormone
Peptides
Insulin-Like Growth Factor Binding Protein 3
Intercellular Signaling Peptides and Proteins
Serum
Insulin
Acids
Pituitary Hormones
Deconvolution
Intravenous Infusions
Hydrocortisone
Blood
Placebos

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Neuroendocrinology of prolonged critical illness : Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. / Van Den Berghe, Greet; De Zegher, Francis; Baxter, Robert C.; Veldhuis, Johannes D; Wouters, Pieter; Schetz, Miet; Verwaest, Charles; Van Der Vorst, Erik; Lauwers, Peter; Bouillon, Roger; Bowers, Cyril Y.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 83, No. 2, 1998, p. 309-319.

Research output: Contribution to journalArticle

Van Den Berghe, G, De Zegher, F, Baxter, RC, Veldhuis, JD, Wouters, P, Schetz, M, Verwaest, C, Van Der Vorst, E, Lauwers, P, Bouillon, R & Bowers, CY 1998, 'Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues', Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 2, pp. 309-319. https://doi.org/10.1210/jc.83.2.309
Van Den Berghe, Greet ; De Zegher, Francis ; Baxter, Robert C. ; Veldhuis, Johannes D ; Wouters, Pieter ; Schetz, Miet ; Verwaest, Charles ; Van Der Vorst, Erik ; Lauwers, Peter ; Bouillon, Roger ; Bowers, Cyril Y. / Neuroendocrinology of prolonged critical illness : Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. In: Journal of Clinical Endocrinology and Metabolism. 1998 ; Vol. 83, No. 2. pp. 309-319.
@article{ee34f899e09c4b249b3e72301334445f,
title = "Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues",
abstract = "The catabolic state of prolonged critical illness is associated with a low activity of the thyrotropic and the somatotropic axes. The neuroendocrine component in the pathogenesis of these low activity states was assessed by investigating the effects of continuous intravenous infusions of TRH, GH- releasing peptide-2 (GHRP-2), and GHRH. Twenty adult patients, critically ill for several weeks, were studied during two consecutive nights. They had been randomly allocated to one of three combinations of peptide infusions, each administered in random order: TRH (one night) and placebo (other night), TRH + GHRP-2 (one night) and GHRP-2 (other night), or TRH + GHRH + GHRP-2 (one night) and GHRH + GHRP-2 (other night). The peptide infusions were started after a 1-μg/kg bolus and infused (1 μg/kg per h) until 0600 h. Blood sampling was performed every 20 min, and pituitary hormone secretion was quantified by deconvolution analysis. Reduced pulsatile fraction of TSH, GH, and PRL secretion and low serum concentrations of T4, T3, insulin growth factor-I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were documented in the untreated state. Infusion of TRH alone or in combination with GH secretagogues augmented nonpulsatile TSH release 2- to 5-fold; only TRH + GHRP-2 increased pulsatile TSH secretion (4-fold). Average rises in T4 (40-54{\%}) and in T3 (52-116{\%}) were obtained with all three combinations, whereas reverse T3 levels did not increase, except when TRH was infused alone. Pulsatile GH secretion was amplified >6- and > 10- fold, respectively, by GHRP-2 and GHRH + GHRP-2 infusions, generating mean increases of serum IGF-I (66{\%} and 106{\%}), IGFBP-3 (50{\%} and 56{\%}), and ALS (65{\%} and 97{\%}) within 45 h. The addition of TRH did not alter the GH secretory patterns. TRH infusion increased PRL release only when combined with GH secretagogues. No effects on serum cortisol were detected. In conclusion, the pathogenesis of the low activity state of the thyrotropic and somatotropic axes in prolonged critical illness appears to have a neuroendocrine component, because these axes are both readily activated by coinfusion of TRH and GH secretagogues.",
author = "{Van Den Berghe}, Greet and {De Zegher}, Francis and Baxter, {Robert C.} and Veldhuis, {Johannes D} and Pieter Wouters and Miet Schetz and Charles Verwaest and {Van Der Vorst}, Erik and Peter Lauwers and Roger Bouillon and Bowers, {Cyril Y.}",
year = "1998",
doi = "10.1210/jc.83.2.309",
language = "English (US)",
volume = "83",
pages = "309--319",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Neuroendocrinology of prolonged critical illness

T2 - Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues

AU - Van Den Berghe, Greet

AU - De Zegher, Francis

AU - Baxter, Robert C.

AU - Veldhuis, Johannes D

AU - Wouters, Pieter

AU - Schetz, Miet

AU - Verwaest, Charles

AU - Van Der Vorst, Erik

AU - Lauwers, Peter

AU - Bouillon, Roger

AU - Bowers, Cyril Y.

PY - 1998

Y1 - 1998

N2 - The catabolic state of prolonged critical illness is associated with a low activity of the thyrotropic and the somatotropic axes. The neuroendocrine component in the pathogenesis of these low activity states was assessed by investigating the effects of continuous intravenous infusions of TRH, GH- releasing peptide-2 (GHRP-2), and GHRH. Twenty adult patients, critically ill for several weeks, were studied during two consecutive nights. They had been randomly allocated to one of three combinations of peptide infusions, each administered in random order: TRH (one night) and placebo (other night), TRH + GHRP-2 (one night) and GHRP-2 (other night), or TRH + GHRH + GHRP-2 (one night) and GHRH + GHRP-2 (other night). The peptide infusions were started after a 1-μg/kg bolus and infused (1 μg/kg per h) until 0600 h. Blood sampling was performed every 20 min, and pituitary hormone secretion was quantified by deconvolution analysis. Reduced pulsatile fraction of TSH, GH, and PRL secretion and low serum concentrations of T4, T3, insulin growth factor-I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were documented in the untreated state. Infusion of TRH alone or in combination with GH secretagogues augmented nonpulsatile TSH release 2- to 5-fold; only TRH + GHRP-2 increased pulsatile TSH secretion (4-fold). Average rises in T4 (40-54%) and in T3 (52-116%) were obtained with all three combinations, whereas reverse T3 levels did not increase, except when TRH was infused alone. Pulsatile GH secretion was amplified >6- and > 10- fold, respectively, by GHRP-2 and GHRH + GHRP-2 infusions, generating mean increases of serum IGF-I (66% and 106%), IGFBP-3 (50% and 56%), and ALS (65% and 97%) within 45 h. The addition of TRH did not alter the GH secretory patterns. TRH infusion increased PRL release only when combined with GH secretagogues. No effects on serum cortisol were detected. In conclusion, the pathogenesis of the low activity state of the thyrotropic and somatotropic axes in prolonged critical illness appears to have a neuroendocrine component, because these axes are both readily activated by coinfusion of TRH and GH secretagogues.

AB - The catabolic state of prolonged critical illness is associated with a low activity of the thyrotropic and the somatotropic axes. The neuroendocrine component in the pathogenesis of these low activity states was assessed by investigating the effects of continuous intravenous infusions of TRH, GH- releasing peptide-2 (GHRP-2), and GHRH. Twenty adult patients, critically ill for several weeks, were studied during two consecutive nights. They had been randomly allocated to one of three combinations of peptide infusions, each administered in random order: TRH (one night) and placebo (other night), TRH + GHRP-2 (one night) and GHRP-2 (other night), or TRH + GHRH + GHRP-2 (one night) and GHRH + GHRP-2 (other night). The peptide infusions were started after a 1-μg/kg bolus and infused (1 μg/kg per h) until 0600 h. Blood sampling was performed every 20 min, and pituitary hormone secretion was quantified by deconvolution analysis. Reduced pulsatile fraction of TSH, GH, and PRL secretion and low serum concentrations of T4, T3, insulin growth factor-I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were documented in the untreated state. Infusion of TRH alone or in combination with GH secretagogues augmented nonpulsatile TSH release 2- to 5-fold; only TRH + GHRP-2 increased pulsatile TSH secretion (4-fold). Average rises in T4 (40-54%) and in T3 (52-116%) were obtained with all three combinations, whereas reverse T3 levels did not increase, except when TRH was infused alone. Pulsatile GH secretion was amplified >6- and > 10- fold, respectively, by GHRP-2 and GHRH + GHRP-2 infusions, generating mean increases of serum IGF-I (66% and 106%), IGFBP-3 (50% and 56%), and ALS (65% and 97%) within 45 h. The addition of TRH did not alter the GH secretory patterns. TRH infusion increased PRL release only when combined with GH secretagogues. No effects on serum cortisol were detected. In conclusion, the pathogenesis of the low activity state of the thyrotropic and somatotropic axes in prolonged critical illness appears to have a neuroendocrine component, because these axes are both readily activated by coinfusion of TRH and GH secretagogues.

UR - http://www.scopus.com/inward/record.url?scp=15644365769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15644365769&partnerID=8YFLogxK

U2 - 10.1210/jc.83.2.309

DO - 10.1210/jc.83.2.309

M3 - Article

C2 - 9467533

AN - SCOPUS:15644365769

VL - 83

SP - 309

EP - 319

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -